Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer

1 Jan 2018

Abstract excerpt

Castration-resistant prostate cancer (CRPC) requires tumors to engage metabolic mechanisms that allow sustained testosterone and/or dihydrotestosterone to stimulate progression. 17β-Hydroxysteroid dehydrogenase type 4 (17βHSD4), encoded by HSD17B4, is thought to inactivate testosterone and dihydrotestosterone by converting them to their respective inert 17-keto steroids. Counterintuitively, HSD17B4 expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to Hormonal Regulation and Hypertension
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29346776
DOI: 10.1016/j.celrep.2017.12.081

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate CancerPMID 29346776Read ↗

Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease ProgressionSemantic proximity Read ↗

HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and BeyondSemantic proximity Read ↗

The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression.Semantic proximity Read ↗

Multi-Omics Profiling Exposes a Metabolic Void in Prostate Cancer Models That Drives Precursor Dependence and Clinical ProgressionSemantic proximity Read ↗

Integrated metabolic and transcriptomic landscapes reveal an obligate reliance on exogenous steroid conversion for prostate cancer survivalSemantic proximity Read ↗

5β-Dihydrotestosterone reveals a mutant androgen receptor vulnerability in prostate cancerSemantic proximity Read ↗

Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuelSemantic proximity Read ↗

Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.Semantic proximity Read ↗

Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolismSemantic proximity Read ↗

Preclinical and Clinical Research Models of Prostate Cancer: A Brief OverviewSemantic proximity Read ↗

Emerging data on androgen receptor splice variants in prostate cancerSemantic proximity Read ↗

Adrenal-Permissive HSD3B1 Genotype-An Invisible Stimulator of Prostate Cancer Mortality.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.